Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

231.99
-3.9500-1.67%
Post-market: 228.20-3.7900-1.63%17:17 EDT
Volume:375.69K
Turnover:87.22M
Market Cap:25.04B
PE:-62.64
High:238.93
Open:234.59
Low:230.23
Close:235.94
Loading ...

BeiGene Is Maintained at Buy by Guggenheim

Dow Jones
·
08 May

BeiGene price target raised to $350 from $348 at Guggenheim

TIPRANKS
·
08 May

RBC Trims Price Target on BeiGene to $311 From $312, Keeps Outperform Rating

MT Newswires Live
·
08 May

Beigene Ltd reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat

Benzinga
·
07 May

Stock Track | BeiGene Plunges 5.25% Pre-Market Despite Strong Q1 Results and Maintained 2025 Guidance

Stock Track
·
07 May

BeiGene Swings to Q1 Adjusted Earnings, Revenue Increases; 2025 Revenue Outlook Reiterated

MT Newswires Live
·
07 May

BeiGene sees FY25 revenue $4.9B-$5.3B, consensus $5.09B

TIPRANKS
·
07 May

CORRECTION: BeiGene Q1 Adj. EPADS $1.22 Beats $(0.74) Estimate, Sales $1.12B Miss $1.14B Estimate

Benzinga
·
07 May

Beigene Ltd expected to post a loss of 74 cents a share - Earnings Preview

Reuters
·
05 May

3 Stocks That Could Be Trading Below Their Estimated Fair Value

Simply Wall St.
·
29 Apr

BeiGene Price Target Maintained With a $312.00/Share by RBC Capital

Dow Jones
·
28 Apr

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
23 Apr

BeiGene Is Maintained at Overweight by JP Morgan

Dow Jones
·
22 Apr

BeiGene to Announce First Quarter 2025 Financial Results on May 7

Business Wire
·
17 Apr

US FDA Animal Testing De-Emphasis May Boost Biotech Innovation, RBC Says

MT Newswires Live
·
11 Apr

BeiGene Price Target Maintained With a $348.00/Share by Guggenheim

Dow Jones
·
10 Apr

BeiGene Initiated at Outperform by RBC Capital

Dow Jones
·
07 Apr

RBC Initiates BeiGene at Outperform With $312 Price Target

MT Newswires Live
·
07 Apr

BUZZ-BeiGene slides after halting lung cancer drug trial due to futility

Reuters
·
03 Apr